

20 March 2019

## **Eye Co Announces Patent Filing Relating to its Treatment for Dry Age-Related Macular Degeneration.**

Eye Co Pty Ltd is pleased to announce that it has filed a PCT application relating to its treatment for Dry Age-Related Macular Degeneration(d-AMD).

As previously announced, Eye Co has received Ethics Committee approval to commence a Phase 1b human safety study with its lead compound, *Fludrocortisone Acetate* in the treatment of d-AMD. That trial, which is underway at Sydney Retina, represents the first time this drug will have been used in humans with retinal disease.

*Fludrocortisone Acetate* is a potential breakthrough treatment of Geographic Atrophy associated with the dry form of AMD.

d-AMD represents a substantial market opportunity as there is currently no registered or available effective treatment for this condition globally. This condition will afflict over 100 million people in the major pharmaceutical markets over the next 10 years.

Professor Philip Penfold, Eye Co's Chief Scientist, said: "I am delighted that we are now in a position to take this product into human studies. With the filing of these patents we are a step closer to making this technology available to the millions of people afflicted with this debilitating condition".

Your sincerely



Peter Abrahamson FAICD  
Managing Director